Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.
Twilio (TWLO) : In his "Know Your IPO" segment, Cramer took a look at Twilio, the cloud communications company that came public last Thursday at $15 a share only to rocket 94% to $29 by the close of its first day and another 3% today.
Cramer explained that Twilio allows companies including Uber, Nordstrom (JWN) and Facebook's (FB) What's App to add real-time communications services to their applications. The company offers everything from voice messaging, call recording, text messages and even embedded video services for developers of all sizes.
Twilio boasts 28,000 active customers and charges fees based on customers' usage, meaning that as Uber and Facebook expand their user bases, Twilio shares in the profits. That's how the company saw 78% revenue growth in 2014 and accelerated that to 88% in 2015.
Twilio is not without some risk factors, however. The company is not profitable and is playing in an unproven market. Twilio also derives 15% of its revenue from a single customer, Facebook, which could decided to built its own platforms.
Then there's Twilio's valuation. The stock now trades at 13 times sales, or factoring in its growth rate, 7.5 times 2016 sales. That's higher than the current valuation of Salesforce.com (CRM) .
But valuation aside, Cramer said he thinks Twilio is a winner on any weakness.
Idexx Labs (IDXX) : In an exclusive interview, Cramer sat down with Jonathan Ayers, chairman and CEO of Idexx Labs, an animal health products and services company.
Ayers said when it comes to our pets and their care, the sky's the limit. That's how a company like Idexx can still see 5% organic growth in times of recession, as the company did in 2009. Pets are not just an American phenomenon. Ayers noted that Idexx sees Europe still as an emerging market for the company, while other countries, like Brazil, have 75 million pets and almost no veterinary care.
Ayers went on to explain that Idexx' new urine analyzer for cats can give pets a voice and tell vets what's wrong in just three minutes, and is more accurate than traditional testing. Since testing is done on a continual basis, Idexx enjoys lots of recurring revenue.
Cramer concluded that Idexx is the type of stock you buy when Brexit takes the entire stock market lower.
To read a full recap of "Mad Money" on CNBC, click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.